NCBiotech News

A public-private partnership has cut the ribbon for a regional industrial wastewater pretreatment facility in Clayton worth $40 million.

Pfizer, the international biopharmaceutical giant, is expanding its gene therapy program with the purchase of a Durham property that will become a clinical manufacturing facility.

Viralgen, a Spanish contract development and manufacturing organization half owned by AskBio of Research Triangle Park, has gained vital regulatory status in Europe for producing gene therapies using AskBio’s manufacturing process.

Thermo Fisher Scientific has a new virtual reality training facility that will mimic real-world operating environments as a way to train new employees on the sterile injectibles drug production lines.

A window of opportunity is opening for qualified Pitt County high school students to take an industry-focused training program after graduation and enter a rewarding, well-paying career in pharmaceutical manufacturing.

North Carolina is a global leader in gene therapy thanks to its renowned workforce development programs and the scientific output of its research universities.

A group representing North Carolina’s BioPharma Crescent has a few more ideas now about such things as cell and gene therapies and digital solutions for pharmaceutical packaging. And a lot of people from around the world are aware of North Carolina’s BioPharma Crescent.

RTP's AskBio has entered a strategic partnership with Boston's Selecta to boost gene therapy's potential for re-dosing if needed.

Merck announced today that it will invest at least $680 million and add some 425 new jobs over the next few years, including an expansion of its Durham vaccine manufacturing facility and a $30 million packaging line addition at its Wilson plant.

Grifols’ product portfolio just got a little larger with U.S. Food and Drug Administration approval of Xembify, a treatment for immune deficiency.

Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there.

 

Novozymes has received an award of up to $2.5 million from the U.S. Department of Energy to find new and more efficient enzymes for turning corn stover into fuel for cars and trucks.

A public/private partnership is providing biology and chemistry majors at the University of North Carolina Wilmington with unique insight into the pharmaceutical services industry.

Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies.

As part of its plans to use only renewable electricity in the U.S., Novo Nordisk is investing $70 million in a 672-acre solar panel installation in southeastern North Carolina’s Pender County.